Encore Medical, Inc.

Business overview

Encore Medical, Inc. develops, manufactures, and markets septal occlusion products designed to repair cardiac defects through nonsurgical methods. Founded in 2017 and located in Eagan, Minnesota, the company has marketed devices in international markets, with CE Mark approval for sales outside the U.S. The company focuses on products for patent foramen ovale (PFO) and atrial septal defects (ASD).

Revenue model

Encore generates revenue primarily through the sales of its septal occlusion devices, which are delivered through catheters. The devices are sold both directly and through distributors, with pricing set based on market conditions and reimbursement structures. In the U.S., they plan to pursue reimbursement under established CPT codes as their devices receive FDA approval.

Competitive strengths

• Proven design with over 35,000 implants
• Low metal content reducing post-implant complications
• CE Mark certification enabling international sales
• Focus on clinical evidence around treatment effectiveness

Risk factors

• Inability to obtain necessary FDA approvals for U.S. sales
• High competition in the medical device market from established players
• Dependence on limited customer base for revenue
• Need for significant capital to fund operations and clinical trials

Use of proceeds

Net proceeds will primarily finance U.S. clinical trials for stroke and migraine indications, as well as support working capital and general corporate uses. Specific allocations include approximately $7.2 million for stroke trials and around $2 million for migraine studies.